| Ramirez, A., van der Flier, W. M., Herold, C., Ramonet, D., Heilmann, S., Lewczuk, P., Popp, J., Lacour, A., Drichel, D., Louwersheimer, E., Kummer, M. P., Cruchaga, C., Hoffmann, P., Teunissen, C., Holstege, H., Kornhuber, J., Peters, O., Naj, A. C., Chouraki, V., Bellenguez, C., Gerrish, Amy, Heun, R., Frolich, L., Hull, M., Buscemi, L., Herms, S., Kolsch, H., Scheltens, P., Breteler, M. M., Ruther, E., Wiltfang, J., Goate, A., Jessen, F., Maier, W., Heneka, M. T., Becker, T. and Nothen, M. M. 2014. SUCLG2 identified as both a determinator of CSF A 1-42 levels and an attenuator of cognitive decline in Alzheimer's disease. Human Molecular Genetics 23 (24) , pp. 6644-6658. 10.1093/hmg/ddu372 |
Abstract
Cerebrospinal fluid amyloid-beta 1-42 (Aβ1-42) and phosphorylated Tau at position 181 (pTau181) are biomarkers of Alzheimer's disease (AD). We performed an analysis and meta-analysis of genome-wide association study data on Aβ1-42 and pTau181 in AD dementia patients followed by independent replication. An association was found between Aβ1-42 level and a single-nucleotide polymorphism in SUCLG2 (rs62256378) (P = 2.5×10(-12)). An interaction between APOE genotype and rs62256378 was detected (P = 9.5 × 10(-5)), with the strongest effect being observed in APOE-ε4 noncarriers. Clinically, rs62256378 was associated with rate of cognitive decline in AD dementia patients (P = 3.1 × 10(-3)). Functional microglia experiments showed that SUCLG2 was involved in clearance of Aβ1-42.
| Item Type: | Article |
|---|---|
| Date Type: | Published Online |
| Status: | Published |
| Schools: | MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG) Medicine |
| Subjects: | R Medicine > R Medicine (General) |
| ISSN: | 0964-6906 |
| Last Modified: | 14 Mar 2019 11:40 |
| URI: | https://orca.cardiff.ac.uk/id/eprint/74873 |
Citation Data
Cited 31 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
 |
Edit Item |
Altmetric
Altmetric
Cardiff University Information Services